Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1201
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-A1201 is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers, particularly advanced or metastatic breast cancer. It consists of a humanized anti-HER2 monoclonal antibody (trastuzumab, IgG1) chemically linked via a lysine-SMCC linker to DM1 (maytansine), a potent microtubule inhibitor. The ADC specifically targets HER2-expressing tumor cells, where it binds to the HER2 antigen on the cell surface, is internalized, and releases DM1 intracellularly to inhibit microtubule polymerization and induce cell death. SHR-A1201 has demonstrated safety and tolerability in phase I clinical trials with encouraging antitumor activity in heavily pretreated patients with advanced HER2-positive breast cancer[1][3][5]. The drug exhibits pharmacokinetic properties typical of ADCs and shows dose-proportional exposure over tested ranges[8].
- Brand names
- SHR-A1201SHR-A-1201SHR-A 1201
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SHR-A1201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1201.